Remifentanil

Generic Name
Remifentanil
Brand Names
Ultiva
Drug Type
Small Molecule
Chemical Formula
C20H28N2O5
CAS Number
132875-61-7
Unique Ingredient Identifier
P10582JYYK
Background

Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.

Indication

For use during the induction and maintenance of general anesthesia.

Associated Conditions
-
Associated Therapies
Immediate postoperative analgesia therapy, Induction and Maintenance of General Anesthesia, Monitored anesthesia care sedation
Clinical Trials
Related News

Remifentanil and Nitroprusside for Controlled Hypotension

Not Applicable
Completed
Conditions
Hypotension, Controlled
Interventions
Drug: nitroprusside
Drug: remifentanil
First Posted Date
2013-12-04
Last Posted Date
2013-12-04
Lead Sponsor
Jeju National University School of Medicine
Target Recruit Count
30
Registration Number
NCT02001298
Locations
🇰🇷

Jeju National University Hospital, Jeju-si, Jeju Special Self-Governing Province, Korea, Republic of

Prothrombotic Factors and Anaesthesia in Prostate Cancer

First Posted Date
2013-12-02
Last Posted Date
2014-11-06
Lead Sponsor
Regina Elena Cancer Institute
Target Recruit Count
200
Registration Number
NCT01998685
Locations
🇮🇹

Department of Anaesthesiology, Regina Elena, National Cancer Institute, Roma, Italy

A Study to Evaluate the Safety and Efficacy of Ultiva (Remifentanil Hydrochloride) in Pediatric Participants General Anesthetised

Phase 3
Completed
Conditions
Anesthesia
Interventions
Drug: Remifentanil
First Posted Date
2013-11-28
Last Posted Date
2015-11-16
Lead Sponsor
Janssen Pharmaceutical K.K.
Target Recruit Count
80
Registration Number
NCT01998165

Combination of Remifentanil and Flurbiprofen in Sedation and Analgesia for ESWL of Pancreatic Stone

First Posted Date
2013-11-28
Last Posted Date
2015-02-04
Lead Sponsor
Changhai Hospital
Target Recruit Count
60
Registration Number
NCT01998217
Locations
🇨🇳

Department of Anesthesiology, Changhai Hospital, Shanghai, Shanghai, China

Remifentanil Use in Pediatric Rigid Bronchoscopy

First Posted Date
2013-09-20
Last Posted Date
2013-09-20
Lead Sponsor
Bezmialem Vakif University
Target Recruit Count
40
Registration Number
NCT01947114
Locations
🇹🇷

Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey

Remimazolam Phase II Cardiac Anesthesia Study

First Posted Date
2013-09-10
Last Posted Date
2020-01-18
Lead Sponsor
Paion UK Ltd.
Target Recruit Count
90
Registration Number
NCT01937767
Locations
🇩🇪

Herzzentrum Leipzig GmbH, Leipzig, Germany

ONSD According to the Position During Laparoscopy

First Posted Date
2013-09-09
Last Posted Date
2014-10-30
Lead Sponsor
Chosun University Hospital
Target Recruit Count
60
Registration Number
NCT01937104
Locations
🇰🇷

Chosun University Hospital, Gwangju, Donggu, Korea, Republic of

Effect of Deep Neuromuscular Block (NMB), Inhalation or TIVA on Pneumoperitoneum.

First Posted Date
2013-08-29
Last Posted Date
2019-05-29
Lead Sponsor
AZ Sint-Jan AV
Target Recruit Count
50
Registration Number
NCT01930747
Locations
🇧🇪

Azsintjan, Brugge, Belgium

Dosing Study of Remifentanil for Smooth Removal of the Laryngeal Mask Airway (LMA)

First Posted Date
2013-08-29
Last Posted Date
2014-10-15
Lead Sponsor
Ajou University School of Medicine
Target Recruit Count
27
Registration Number
NCT01931683
Locations
🇰🇷

Ajou University School of Medicine, Suwon, Korea, Republic of

Opioid Effects on Swallowing Comparing Younger and Elderly Volunteers

First Posted Date
2013-08-16
Last Posted Date
2014-12-03
Lead Sponsor
Region Örebro County
Target Recruit Count
18
Registration Number
NCT01924234
Locations
🇸🇪

Örebro University Hospital, Örebro, Sweden

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy